Terminated PHASE1/PHASE2 INTERVENTIONAL 6-arm NCT04082936

A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma

A Phase 1/2 Open-label, Multicenter Study Evaluating the Safety and Pharmacokinetics of Imvotamab (IGM-2323) as a Single Agent and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphomas

Sponsor: ADC Therapeutics S.A.

Conditions DLBCL Follicular Lymphoma Mantle Cell Lymphoma Marginal Zone Lymphoma Non-Hodgkin Lymphoma

Interventions imvotamab

Updated 20 times since 2019 Last updated: Jul 23, 2024 Started: Sep 30, 2019 Primary completion: Feb 16, 2024 Completion: Feb 22, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Strategic Pipeline Prioritization: Clinical development of imvotamab in autoimmune diseases prioritized.

Other terminated trials from ADC Therapeutics S.A.

More terminations from ADC Therapeutics S.A.

Listed as NCT04082936, this PHASE1/PHASE2 trial focuses on DLBCL and Follicular Lymphoma and remains terminated or withdrawn. Sponsored by ADC Therapeutics S.A., it has been updated 20 times since 2019, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

20 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE1/PHASE2
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE1/PHASE2
Aug 2024 — Sep 2024 [monthly]

Terminated PHASE1/PHASE2

Status: Active Not Recruiting → Terminated
Jul 2024 — Aug 2024 [monthly]

Active Not Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Dec 2023 — Jul 2024 [monthly]

Active Not Recruiting PHASE1_PHASE2

▶ Show 15 earlier versions

Nov 2023 — Dec 2023 [monthly]

Active Not Recruiting PHASE1_PHASE2

Status: Recruiting → Active Not Recruiting
Feb 2023 — Nov 2023 [monthly]

Recruiting PHASE1_PHASE2
Nov 2022 — Feb 2023 [monthly]

Recruiting PHASE1_PHASE2
Apr 2022 — Nov 2022 [monthly]

Recruiting PHASE1_PHASE2

Phase: PHASE1 → PHASE1_PHASE2
Oct 2021 — Apr 2022 [monthly]

Recruiting PHASE1
Jun 2021 — Oct 2021 [monthly]

Recruiting PHASE1
May 2021 — Jun 2021 [monthly]

Recruiting PHASE1
Mar 2021 — May 2021 [monthly]

Recruiting PHASE1
Feb 2021 — Mar 2021 [monthly]

Recruiting PHASE1
Jan 2021 — Feb 2021 [monthly]

Recruiting PHASE1
Nov 2020 — Jan 2021 [monthly]

Recruiting PHASE1
Mar 2020 — Nov 2020 [monthly]

Recruiting PHASE1
Jan 2020 — Mar 2020 [monthly]

Recruiting PHASE1
Nov 2019 — Jan 2020 [monthly]

Recruiting PHASE1
Oct 2019 — Nov 2019 [monthly]

Recruiting PHASE1

First recorded

Sep 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

ADC Therapeutics S.A.
IGM Biosciences, Inc.

Data source: IGM Biosciences, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Barcelona, Spain , Bergamo, Italy , Bologna, Italy , Boston, United States , Clayton, Australia , Duarte, United States , Fitzroy, Australia , Houston, United States , Louisville, United States , Madrid, Spain and 10 more locations